622 related articles for article (PubMed ID: 32348641)
1. Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.
Haberman R; Axelrad J; Chen A; Castillo R; Yan D; Izmirly P; Neimann A; Adhikari S; Hudesman D; Scher JU
N Engl J Med; 2020 Jul; 383(1):85-88. PubMed ID: 32348641
[No Abstract] [Full Text] [Related]
2. Biologics, spondylitis and COVID-19.
Rosenbaum JT; Hamilton H; Choi D; Weisman MH; Reveille JD; Winthrop KL
Ann Rheum Dis; 2020 Dec; 79(12):1663-1665. PubMed ID: 32522741
[No Abstract] [Full Text] [Related]
3. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
Hasseli R; Mueller-Ladner U; Schmeiser T; Hoyer BF; Krause A; Lorenz HM; Regierer AC; Richter JG; Strangfeld A; Voll RE; Pfeil A; Schulze-Koops H; Specker C
RMD Open; 2020 Sep; 6(2):. PubMed ID: 32878994
[TBL] [Abstract][Full Text] [Related]
4. Biologics in systemic autoimmune diseases during COVID-19 pandemic.
Annapureddy N; Nalleballe K; Onteddu SR; Sharma R; Sheng S; Kovvuru S; Siddamreddy S; Mandhadi R
Clin Rheumatol; 2020 Dec; 39(12):3529-3531. PubMed ID: 33011932
[No Abstract] [Full Text] [Related]
5. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.
Sanchez-Piedra C; Diaz-Torne C; Manero J; Pego-Reigosa JM; Rúa-Figueroa Í; Gonzalez-Gay MA; Gomez-Reino J; Alvaro-Gracia JM;
Ann Rheum Dis; 2020 Jul; 79(7):988-990. PubMed ID: 32503857
[No Abstract] [Full Text] [Related]
6. Should patients stop their biologic treatment during the COVID-19 pandemic.
Bashyam AM; Feldman SR
J Dermatolog Treat; 2020 Jun; 31(4):317-318. PubMed ID: 32191143
[No Abstract] [Full Text] [Related]
7. How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion.
Sarzi-Puttini P; Marotto D; Antivalle M; Salaffi F; Atzeni F; Maconi G; Monteleone G; Rizzardini G; Antinori S; Galli M; Ardizzone S
Autoimmun Rev; 2020 Jul; 19(7):102574. PubMed ID: 32376399
[TBL] [Abstract][Full Text] [Related]
8. Thoughts on COVID-19 and autoimmune diseases.
Askanase AD; Khalili L; Buyon JP
Lupus Sci Med; 2020; 7(1):e000396. PubMed ID: 32341791
[TBL] [Abstract][Full Text] [Related]
9. Should biologics for psoriasis be interrupted in the era of COVID-19?
Lebwohl M; Rivera-Oyola R; Murrell DF
J Am Acad Dermatol; 2020 May; 82(5):1217-1218. PubMed ID: 32199889
[No Abstract] [Full Text] [Related]
10. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Gianfrancesco M; Hyrich KL; Al-Adely S; Carmona L; Danila MI; Gossec L; Izadi Z; Jacobsohn L; Katz P; Lawson-Tovey S; Mateus EF; Rush S; Schmajuk G; Simard J; Strangfeld A; Trupin L; Wysham KD; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Wallace ZS; Yazdany J; Machado PM; Robinson PC;
Ann Rheum Dis; 2020 Jul; 79(7):859-866. PubMed ID: 32471903
[TBL] [Abstract][Full Text] [Related]
11. COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution.
Kansal NK
J Am Acad Dermatol; 2020 Jun; 82(6):e213. PubMed ID: 32246966
[No Abstract] [Full Text] [Related]
12. [Autoimmune diseases in the context of pandemic COVID-19].
Horisberger A; Moi L; Ribi C; Comte D
Rev Med Suisse; 2020 Apr; 16(N° 691-2):827-830. PubMed ID: 32348045
[TBL] [Abstract][Full Text] [Related]
13. Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs.
Conti A; Lasagni C; Bigi L; Pellacani G
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e360-e361. PubMed ID: 32379913
[No Abstract] [Full Text] [Related]
14. How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology.
Jessica Chang TY; Pope JE
Immunotherapy; 2020 Oct; 12(15):1115-1119. PubMed ID: 32640861
[No Abstract] [Full Text] [Related]
15. Preliminary Data Suggests That Biologics in Dermatology Are Not Associated With Adverse COVID-19 Outcomes.
Nassim D; Jfri A; Litvinov IV; Netchiporouk E
J Cutan Med Surg; 2020; 24(4):420-421. PubMed ID: 32449619
[No Abstract] [Full Text] [Related]
16. Challenges in paediatric inflammatory bowel diseases in the COVID-19 time.
Dipasquale V; Cucchiara S; Martinelli M; Miele E; Aloi M; Romano C
Dig Liver Dis; 2020 May; 52(5):593-594. PubMed ID: 32276846
[No Abstract] [Full Text] [Related]
17. Asthma, biologics, corticosteroids, and coronavirus disease 2019.
Akenroye AT; Wood R; Keet C
Ann Allergy Asthma Immunol; 2020 Jul; 125(1):12-13. PubMed ID: 32387535
[No Abstract] [Full Text] [Related]
18. Guttate psoriasis secondary to COVID-19.
Gananandan K; Sacks B; Ewing I
BMJ Case Rep; 2020 Aug; 13(8):. PubMed ID: 32784237
[No Abstract] [Full Text] [Related]
19. Systemic Inflammation With Cardiac Involvement in Pediatric Patients With Evidence of COVID-19 in a Community Hospital in the Bronx, New York.
Rogo T; Mathur K; Purswani M
J Pediatric Infect Dis Soc; 2020 Sep; 9(4):502-503. PubMed ID: 32687574
[No Abstract] [Full Text] [Related]
20. [Chronic inflammatory bowel disease and COVID-19].
Moum B
Tidsskr Nor Laegeforen; 2020 May; 140(7):. PubMed ID: 32378846
[No Abstract] [Full Text] [Related]
[Next] [New Search]
